<SEC-DOCUMENT>0001558370-21-010404.txt : 20210805
<SEC-HEADER>0001558370-21-010404.hdr.sgml : 20210805
<ACCEPTANCE-DATETIME>20210805080108
ACCESSION NUMBER:		0001558370-21-010404
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20210730
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210805
DATE AS OF CHANGE:		20210805

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GLYCOMIMETICS INC
		CENTRAL INDEX KEY:			0001253689
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36177
		FILM NUMBER:		211146393

	BUSINESS ADDRESS:	
		STREET 1:		9708 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		240-243-1201

	MAIL ADDRESS:	
		STREET 1:		9708 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>glyc-20210730x8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.7811.37134 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 8/5/2021 12:00:29 PM -->
      <!-- iXBRL Library version: 1.0.7811.37150 -->
      <!-- iXBRL Service Job ID: 767a3ab1-fb1c-4415-a79e-689cd6bb4b99 -->

  <html xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:glyc="http://www.glycomimetics.com/20210730" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_7_30_2021_To_7_30_2021_pgCzPkHsLUKLmV_c3rdOlA" name="dei:EntityCentralIndexKey" id="Tc_7pF5awmX50aep2Cm-n7kKw_2_1">0001253689</ix:nonNumeric><ix:nonNumeric contextRef="Duration_7_30_2021_To_7_30_2021_pgCzPkHsLUKLmV_c3rdOlA" name="dei:AmendmentFlag" id="Tc_5XSJHcwKxEmyICLU4DGEVQ_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="glyc-20210730.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_7_30_2021_To_7_30_2021_pgCzPkHsLUKLmV_c3rdOlA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001253689</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-30</xbrli:startDate><xbrli:endDate>2021-07-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:9.41%;padding-right:9.41%;position:relative;"><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;border-top:9pt double #000000;margin:0pt;"><span style="text-decoration:underline;visibility:hidden;">&#8203;</span></p><a id="_f1dcd9e9_0220_4da9_9b7a_0567b55b4fc9"></a><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;letter-spacing:-0.1pt;line-height:1.19;text-align:center;margin:0pt;">UNITED STATES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;letter-spacing:-0.1pt;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.1pt;">Washington, DC 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.1pt;">FORM </b><ix:nonNumeric contextRef="Duration_7_30_2021_To_7_30_2021_pgCzPkHsLUKLmV_c3rdOlA" name="dei:DocumentType" id="Narr_rB8GysNTm0CSPr1mrf-ppw"><b style="font-weight:bold;letter-spacing:-0.1pt;">8-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.1pt;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.1pt;">Pursuant to Section 13 or 15(d) of</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:-0.1pt;">The Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:9pt;font-weight:bold;letter-spacing:-0.1pt;">Date of Report (Date of earliest event reported):</b><b style="font-size:9pt;font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_7_30_2021_To_7_30_2021_pgCzPkHsLUKLmV_c3rdOlA" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_14BQy5fNDESIeHefXvN9Yg"><b style="font-size:9pt;font-weight:bold;">July 30, 2021</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:14pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_30_2021_To_7_30_2021_pgCzPkHsLUKLmV_c3rdOlA" name="dei:EntityRegistrantName" id="Narr_ZDhKYrryGEOTnV4VzyrpOg"><b style="font-weight:bold;letter-spacing:-0.1pt;">GlycoMimetics, Inc.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:-0.1pt;">(Exact name of registrant as specified in its charter)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><a id="_e1f4de58_61bd_4709_b865_8049cd6378dd"></a><a id="Tc_8ICDh-T__Uq5md0DIJyQ1g_2_0"></a><a id="Tc_GjtxgX8fckiazv64JmEEpA_2_2"></a><a id="Tc_4oxF52H4eUqWCTLTFUTCtA_2_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:29.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:31.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:32.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:29.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_30_2021_To_7_30_2021_pgCzPkHsLUKLmV_c3rdOlA" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_2jA8yP7LH0K-TKRlJg7mHg_1_0"><b style="font-size:9pt;font-weight:bold;letter-spacing:-0.1pt;text-decoration:underline;text-decoration-color:#000000;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:3.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_30_2021_To_7_30_2021_pgCzPkHsLUKLmV_c3rdOlA" name="dei:EntityFileNumber" id="Tc_GkDDAviZLUSXLrs5waAuKw_1_2"><b style="font-size:9pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">001-36177</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;font-weight:bold;letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_30_2021_To_7_30_2021_pgCzPkHsLUKLmV_c3rdOlA" name="dei:EntityTaxIdentificationNumber" id="Tc_7vp7CK_TPUKnRyH7aQ9HCg_1_4"><b style="font-size:9pt;font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">06-1686563</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:29.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:-0.1pt;">(State or other jurisdiction of</span> <span style="letter-spacing:-0.1pt;">incorporation)</span></p></td><td style="vertical-align:bottom;width:3.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:31.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:-0.1pt;">(Commission File Number)</span></p></td><td style="vertical-align:bottom;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:32.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:-0.1pt;">(IRS Employer</span><br /><span style="letter-spacing:-0.1pt;">Identification No.)</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_30_2021_To_7_30_2021_pgCzPkHsLUKLmV_c3rdOlA" name="dei:EntityAddressAddressLine1" id="Narr_7K99Wy0vw0S8TFC3b_ge-A"><b style="font-size:9pt;font-weight:bold;">9708 Medical Center Drive</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_30_2021_To_7_30_2021_pgCzPkHsLUKLmV_c3rdOlA" name="dei:EntityAddressCityOrTown" id="Narr_nXbpgFF33ESPynckHtTs9w"><b style="font-size:9pt;font-weight:bold;">Rockville</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_7_30_2021_To_7_30_2021_pgCzPkHsLUKLmV_c3rdOlA" name="dei:EntityAddressStateOrProvince" id="Narr_NRYXfi3OjUq42Cg6VYh_Bw"><b style="font-size:9pt;font-weight:bold;">MD</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_7_30_2021_To_7_30_2021_pgCzPkHsLUKLmV_c3rdOlA" name="dei:EntityAddressPostalZipCode" id="Narr_qrzltJ6f0kSHdZFw4vUVTQ"><b style="font-size:9pt;font-weight:bold;">20850</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:-0.1pt;">(Address of principal executive offices, including zip code)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_7_30_2021_To_7_30_2021_pgCzPkHsLUKLmV_c3rdOlA" name="dei:CityAreaCode" id="Narr_IHIzlBC55E6OLvQJKRLC1g"><b style="font-size:9pt;font-weight:bold;">240</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_7_30_2021_To_7_30_2021_pgCzPkHsLUKLmV_c3rdOlA" name="dei:LocalPhoneNumber" id="Narr_ZfIdqT63I02X_zlC96ISpQ"><b style="font-size:9pt;font-weight:bold;">243-1201</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:-0.1pt;">(Registrant&#8217;s telephone number, including area code)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">N/A</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><span style="letter-spacing:-0.1pt;">(Former name or former address, if changed since last report)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:14.25pt;text-indent:-14.25pt;margin:5pt 0pt 5pt 0pt;"><ix:nonNumeric contextRef="Duration_7_30_2021_To_7_30_2021_pgCzPkHsLUKLmV_c3rdOlA" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Narr_4xoBKF3khkOXMkANYIlx9g"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric><span style="font-size:9pt;"> Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:14.25pt;text-indent:-14.25pt;margin:5pt 0pt 5pt 0pt;"><ix:nonNumeric contextRef="Duration_7_30_2021_To_7_30_2021_pgCzPkHsLUKLmV_c3rdOlA" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Narr_beRiTy4ESEGWT3EnXu3pgQ"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric><span style="font-family:'Segoe UI Symbol';font-size:9pt;"> </span><span style="font-size:9pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:14.25pt;text-indent:-14.25pt;margin:5pt 0pt 5pt 0pt;"><ix:nonNumeric contextRef="Duration_7_30_2021_To_7_30_2021_pgCzPkHsLUKLmV_c3rdOlA" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Narr_H0BFx0MWyUyY2JArNA954g"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric><span style="font-family:'Segoe UI Symbol';font-size:9pt;"> </span><span style="font-size:9pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.1pt;padding-left:14.25pt;text-indent:-14.25pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_7_30_2021_To_7_30_2021_pgCzPkHsLUKLmV_c3rdOlA" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Narr_CDZ3HTtu8E-XOgD7eiZGcA"><span style="font-family:'Segoe UI Symbol';font-size:9pt;letter-spacing:0pt;">&#9744;</span></ix:nonNumeric><span style="font-size:9pt;letter-spacing:0pt;"> Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.1pt;padding-left:14.25pt;text-indent:-14.25pt;margin:0pt;"><span style="font-size:9pt;letter-spacing:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Securities registered pursuant to Section 12(b) of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><a id="_815aaab8_f3ad_460f_b7c2_43bd0f552b4c"></a><div style="margin-left:0pt;"><a id="Tc_R6jHzUAJlU24E7M4j9FSpg_1_0"></a><a id="Tc_buLlhnovFEC-L2RRISoUgg_1_1"></a><a id="Tc_zEgCmIL7aUib8S7-AFvKaA_1_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:97.58%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.34%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:22.29%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:44.35%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:33.34%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:5pt 0pt 5pt 0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Title of each class</b></p></td><td style="vertical-align:top;width:22.29%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:5pt 0pt 5pt 0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Trading Symbol(s)</b></p></td><td style="vertical-align:top;width:44.35%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:5pt 0pt 5pt 0pt;"><b style="font-weight:bold;text-decoration:underline;text-decoration-color:#000000;">Name of each exchange on which registered</b></p></td></tr><tr><td style="vertical-align:top;width:33.34%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:5pt 0pt 5pt 0pt;"><ix:nonNumeric contextRef="Duration_7_30_2021_To_7_30_2021_pgCzPkHsLUKLmV_c3rdOlA" name="dei:Security12bTitle" id="Tc_F0jw50_sMUCPG2VbMb4U_A_2_0"><span style="font-size:9pt;">Common Stock, $0.001 par value</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:22.29%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:5pt 0pt 5pt 0pt;"><ix:nonNumeric contextRef="Duration_7_30_2021_To_7_30_2021_pgCzPkHsLUKLmV_c3rdOlA" name="dei:TradingSymbol" id="Tc_Vmada2zcaEO2f3Olx6y-kg_2_1"><span style="font-size:9pt;">GLYC</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:44.35%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:5pt 0pt 5pt 0pt;"><ix:nonNumeric contextRef="Duration_7_30_2021_To_7_30_2021_pgCzPkHsLUKLmV_c3rdOlA" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc_qOEo9bOdsk-tOzW80vbm5A_2_2"><span style="font-size:9pt;">The Nasdaq Stock Market</span></ix:nonNumeric></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.1pt;padding-left:14.25pt;text-indent:-14.25pt;margin:0pt;"><span style="font-size:9pt;letter-spacing:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;">Emerging growth company </span><ix:nonNumeric contextRef="Duration_7_30_2021_To_7_30_2021_pgCzPkHsLUKLmV_c3rdOlA" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_DHBOx83_s0qVgv8ygl3ixg"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><div style="margin-left:0pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;width:97.58%;"><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"> <span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:22.3%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:44.35%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr style="height:1pt;"><td style="vertical-align:top;width:33.33%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:22.3%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:44.35%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;border-bottom:9pt double #000000;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Courier New';line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:81.18%;border:0;margin:30pt 9.41% 30pt 9.41%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_f382fb43_925f_4aa6_acc8_fe4692457c14"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;">Item 2.02 &#160;</b></span><b style="font-weight:bold;">Results of Operations and Financial Condition.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On August 5, 2021, GlycoMimetics, Inc. (the &#8220;<span style="font-style:italic;font-weight:bold;">Company</span>&#8221;) issued a press release announcing its financial results for the second quarter ended June 30, 2021. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report and is incorporated herein by reference. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In accordance with General Instruction B.2. of Form 8-K, the information in this Item 2.02, and Exhibit 99.1 hereto, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;<span style="font-style:italic;font-weight:bold;">Exchange Act</span>&#8221;), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any of the Company&#8217;s filings under the Securities Act of 1933, as amended (the &#8220;<span style="font-style:italic;font-weight:bold;">Securities Act</span>&#8221;), or the Exchange Act, whether made before or after the date hereof, regardless of any incorporation language in such a filing, except as expressly set forth by specific reference in such a filing. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;">Item 5.02</b></span><b style="font-weight:bold;">Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:left;">(b) (e)</span></span><span style="display:inline-block;width:36pt;"></span><span style="font-style:italic;font-weight:bold;">Retirement of Rachel King as President and Chief Executive Officer</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On July 30, 2021, Rachel K. King, President and Chief Executive Officer of the Company, notified the Board of Directors of the Company (the &#8220;<span style="font-style:italic;font-weight:bold;">Board</span><span style="white-space:pre-wrap;">&#8221;) of her decision to retire from those positions, effective as of August 6, 2021.  Mrs. King will remain as an employee of the Company until August 31, 2021.  &#160;</span><span style="white-space:pre-wrap;">   </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Following her retirement, Mrs. King will continue to serve on the Board, which will constitute Continuous Service under the Company&#8217;s 2013 Equity Incentive Plan (the &#8220;<span style="font-style:italic;font-weight:bold;">2013 Plan</span><span style="white-space:pre-wrap;">&#8221;) for purposes of continued vesting of her stock options.  She will receive the same compensation as the other non-employee members of the Board under the Company&#8217;s policy for compensation of non-employee directors, which was filed as Exhibit 10.14 to the Company&#8217;s Form 10-K for the year ended December 31, 2020.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">On August 3, 2021, the Company and Mrs. King entered into a consulting agreement under which she will continue to provide services to the Company as requested, up to 20 hours per week, through August 31, 2022.  In consideration for such services, Mrs. King will receive a monthly consulting fee of $23,304.17 per month.  Mrs. King will not receive the second half of the retention bonus awarded in September 2019 that she would have been entitled to receive in September 2021.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:left;white-space:pre-wrap;"> (c)(d)(e)</span></span><span style="font-style:italic;font-weight:bold;">Appointment of Harout Semerjian as President and Chief Executive Officer</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">On August 2, 2021, the Board appointed Harout Semerjian as the Company&#8217;s President and Chief Executive Officer, effective as of August 6, 2021.  In connection with Mr. Semerjian&#8217;s appointment as President and Chief Executive Officer, on August 2, 2021 the Board also expanded the authorized size of the Board from seven to eight members and appointed Mr. Semerjian to fill the newly created vacancy, to be effective concurrently with the effectiveness of his appointment as President and Chief Executive Officer.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">Mr. Semerjian will serve in the class of directors whose term will expire at the Company 2022 Annual Meeting of Stockholders. The Company does not expect that Mr. Semerjian will be named as a member of any committees of the Board.  There is no arrangement or understanding between Mr. Semerjian and any other person pursuant to which he was selected as an officer or director of the Company.  There are no related party transactions between Mr. Semerjian and the Company that would require disclosure under Item 404(a) of Regulation S-K, and there is no family relationship between Mr. Semerjian and any of the Company&#8217;s other directors or executive officers.    </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Additional biographical information about Mr. Semerjian is set forth below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">Harout Semerjian, age 50, served as President and Chief Executive Officer of Immunomedics, Inc., a pharmaceutical company, from April 2020 to May 2020. He has most recently been working as an independent advisor serving private equity firms focused on healthcare. From March 2018 to April 2020, he served as Executive Vice President, Chief Commercial Officer at Ipsen Pharma, where he was accountable for the worldwide commercialization and portfolio strategy across oncology, neurosciences and rare diseases. From February 2017 to February 2018, he served as Ipsen&#8217;s President, Head of Specialty Care International Region &amp; Global Franchises.  Mr. Semerjian previously spent 16 years at Novartis Oncology, where he held various worldwide strategic and operational positions, culminating in his last role as Senior Vice President, Global Head for Ribociclib, accountable for worldwide launch preparations. During his tenure at Novartis, Mr. Semerjian worked on numerous launches and commercial activities for various therapies, including Gleevec, Tasigna, Exjade/Jadenu, Promacta, Zometa, and Femara.  Mr. Semerjian holds an M.B.A. from Cornell University, an M.B.A. from Queen&#8217;s University, Canada, and a B.S. in Biology from the Lebanese American University in Lebanon.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company has entered into an employment agreement with Mr.&#160;Semerjian (the &#8220;<span style="font-style:italic;font-weight:bold;">Employment Agreement</span>&#8221;), effective as of August 3, 2021 (the &#8220;<span style="font-style:italic;font-weight:bold;">Effective Date</span>&#8221;), pursuant to which Mr.&#160;<span style="white-space:pre-wrap;">Semerjian will become President and Chief Executive Officer as of August 6, 2021.  He will receive an annual base salary of $595,000 per year, subject to review and adjustment from time to time by the Board in its sole discretion.  The Company will also pay Mr. Semerjian a sign-on bonus of $200,000 in two installments, less applicable tax withholdings. The first installment will be paid within 30 days of the Effective Date, and the second installment will be paid on the first anniversary of the Effective Date, subject to Mr. Semerjian remaining employed by the Company as of that date.  In the event that Mr. Semerjian resigns without &#8220;good reason&#8221; or is terminated for &#8220;cause&#8221; (as such terms are defined in the Employment Agreement), he would be obligated to repay to the Company a prorated portion of the applicable installment of the sign-on bonus. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">Mr. Semerjian will be eligible to receive a target annual bonus per calendar year in an amount equal to 55% of his annual base salary, subject to the discretion of the Board. For 2021, his bonus will be prorated based on the number of days during the calendar year in which he is employed by the Company.  Mr.&#160;</span><span style="white-space:pre-wrap;">Semerjian is also eligible to participate in the Company&#8217;s employee and executive benefit plans and programs as may be maintained by the Company from time to time.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">The Employment Agreement provides for an employment term of four (4) years from the Effective Date.  Unless the Company gives notice of its intent not to renew, or Mr. Semerjian gives written notice to the Company of his determination not to renew, in any case at least one year prior to the fourth anniversary of the Effective Date, the Employment Agreement shall be renewed for one year from that anniversary.  Thereafter, unless the Company or Mr. Semerjian gives written notice of determination not to renew at least one year prior to the next succeeding anniversary of the Effective Date, the Employment Agreement shall be renewed for one year from that anniversary. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In addition, and pursuant to the terms of the Employment Agreement, on August 3, 2021 (the &#8220;<span style="font-style:italic;font-weight:bold;">Grant Date</span>&#8221;), the Board approved the grant of options (the &#8220;<span style="font-style:italic;font-weight:bold;">Option Grants</span>&#8221;) to Mr.&#160;Semerjian to purchase shares of the Company&#8217;s common stock, par value $0.001 per share (the &#8220;<span style="font-style:italic;font-weight:bold;">Common Stock</span>&#8221;) as follows: (a)&#160;an option to purchase 1,098,400 shares, subject to vesting as to 25% of the underlying shares on August 3, 2022 and as to the remaining underlying shares in equal monthly installments over 36 months thereafter, subject to Mr.&#160;Semerjian&#8217;s continued service through each such vesting date, and (b)&#160;an option to purchase 549,200 shares, one-half of which will vest upon FDA approval of the Company&#8217;s product candidate uproleselan as a treatment for relapsed/refractory acute myeloid leukemia and the remainder will vest upon the first commercial sale of uproleselan in the United States or abroad, subject in each case to Mr.&#160;Semerjian&#8217;s continued service through the applicable vesting date. The Option Grants have an exercise price of $2.03 per share, the closing price of the Common Stock on the Grant Date, and are subject to the terms and conditions of the award agreements pursuant to which they are granted. Mr.&#160;Semerjian will remain eligible for additional future stock option and other equity awards as may be determined by the Board, or a committee thereof, in accordance with the 2013 Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">Under the Employment Agreement, if Mr. Semerjian&#8217;s employment with the Company ends due to his resignation for &#8220;good reason&#8221; or his termination by the Company other than for &#8220;cause,&#8221; each as defined in the Employment Agreement, in either case that does not occur within 12 months after the effective date of a Change in Control (as defined in the Employment Agreement), he is entitled to receive (i) continuation of his then-current base salary for a period of 18 months; (ii) a lump sum payment equivalent to the unpaid bonus he would have otherwise earned for the prior calendar year had he remained employed through the date bonuses are regularly paid to senior executives; and (iii) continued health benefits under COBRA for up to 18 months, or if earlier, the date he is eligible for comparable replacement coverage under a subsequent employer&#8217;s group health plan.  </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In the case of Mr. Semerjian&#8217;s termination of employment by the Company other than for &#8220;cause&#8221; or his resignation for &#8220;good reason,&#8221; in either case that occurs within 12 months after the effective date of a Change in Control (as defined in the Employment Agreement), then he is entitled to receive (i) a lump sum severance payment equal to 18 months of his then-current base salary, to be paid on the 60<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> day following the termination, (ii) continued health benefits under COBRA for up to 18 months, or if earlier, the date he is eligible for comparable replacement coverage under a subsequent employer&#8217;s group health plan, (iii) acceleration of all unvested equity awards at the time that such termination occurs, which will be deemed to have vested as of his employment termination date, and (iv) a payment equal to 1.5 times his then current annual target bonus, to be paid on the 60<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> day following the termination. The benefits described in this paragraph are conditioned, among other things, on Mr. Semerjian&#8217;s compliance with his post-termination obligations under the Employment Agreement and his execution of a general release of claims in favor of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">If the post-termination amounts payable constitute &#8220;parachute payments&#8221; under Section 280G of the Internal Revenue Code of 1986, as amended (the &#8220;<span style="font-style:italic;font-weight:bold;">Code</span>&#8221;), and are subject to the excise tax under Section 4999 of the Code, then such payments will either (1) be paid in full or (2) reduced so that the Section 4999 excise tax does not apply, whichever results in the greater after-tax economic benefit to Mr. Semerjian.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The foregoing description of the terms of the Employment Agreement is a summary and does not purport to be complete and is qualified in its entirety by reference to the full text of the Employment Agreement, which will be filed as an exhibit to the Company&#8217;s Quarterly Report on Form&#160;10-Q&#160;for the quarter ending September 30, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="white-space:pre-wrap;">In connection with his employment, Mr. Semerjian also entered into the Company&#8217;s standard form of Confidential Information and Invention Assignment Agreement.  In connection with his appointment as President and Chief Executive Officer and a director of the Company, he is expected to enter into the Company&#8217;s standard form of Indemnification Agreement, which was filed as Exhibit 10.15 to the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Item 7.01</b></span><b style="font-weight:bold;">Regulation FD Disclosure.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-family:'Tms Rmn';">&#160;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-family:'Tms Rmn';white-space:pre-wrap;">On August 4, 2021, the Company issued a press release announcing Mrs. King&#8217;s retirement and Mr. Semerjian&#8217;s appointment.  A copy of this press release is furnished herewith as Exhibit 99.2 to this Current Report. The information contained in the press release furnished as Exhibit 99.2 shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act and is not incorporated by reference into any of the Company&#8217;s filings under the Securities Act or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in any such filing. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-family:'Tms Rmn';margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:72pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:justify;">Item 8.01&#160;&#160;</b></span><b style="font-weight:bold;">Other Events.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On August 2, 2021, the Compensation Committee of the Board adopted an amendment to the GlycoMimetics, Inc. Inducement Plan (the &#8220;<span style="font-style:italic;font-weight:bold;">Inducement Plan</span><span style="white-space:pre-wrap;">&#8221;) to increase the number of shares of Common Stock reserved for issuance under the Inducement Plan from 500,000 shares to 2,000,000 shares, subject to adjustment for stock dividends, stock splits, or other changes in the Common Stock or capital structure.  The Option Grants to Mr. Semerjian described above were granted from the Inducement Plan.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Item 9.01 Financial Statements and Exhibits.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;white-space:pre-wrap;"> (d)&#160;Exhibits</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:79.99%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:10.27%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:1.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:88.13%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:10.27%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;min-height:8.0pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b></p></td><td style="vertical-align:top;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:8.0pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:88.13%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;min-height:8.0pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;min-height:8.0pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number</b></p></td><td style="vertical-align:top;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;min-height:8.0pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:88.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;min-height:8.0pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;Description</b></p></td></tr><tr><td style="vertical-align:top;width:10.27%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><span style="font-size:10pt;">9</span>9.1</p></td><td style="vertical-align:top;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.13%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="glyc-20210730xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Press Release, dated August 5, 2021, &#8220;GlycoMimetics Reports Highlights and Financial Results for Second Quarter 2021&#8221;</span></a> </p></td></tr><tr><td style="vertical-align:top;width:10.27%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.13%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.27%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">99.2</p></td><td style="vertical-align:top;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.13%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;" href="glyc-20210730xex99d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-align:justify;">Press Release, dated August 4, 2021, &#8220;GlycoMimetics Names Harout Semerjian as New Chief Executive Officer to Succeed Retiring CEO Rachel King.&#8221;</span></a></p></td></tr><tr><td style="vertical-align:top;width:10.27%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.13%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:10.27%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">104</p></td><td style="vertical-align:top;width:1.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:5pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:88.13%;margin:0pt;padding:0pt 0.69pt 0pt 0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.41%;border:0;margin:30pt 10.29% 30pt 10.29%;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0.05pt;margin:0pt;"><span style="font-size:0.05pt;visibility:hidden;">&#8203;</span></p><a id="_12a74ceb_ccc6_41ba_ade1_0ae8075e82a5"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;letter-spacing:-0.1pt;line-height:1.19;text-align:center;margin:0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;letter-spacing:-0.1pt;text-align:justify;text-indent:37.05pt;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0.7pt;padding-right:0.7pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:29.85%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:1pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;</b></p></div></div></td><td style="vertical-align:top;width:20.14%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:29.85%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.14%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">GLYCOMIMETICS, INC.</p></td></tr><tr><td style="vertical-align:top;width:29.85%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.14%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:29.85%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.14%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="letter-spacing:-0.1pt;">By:&#160;&#160;</span></p></td><td style="vertical-align:top;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="letter-spacing:-0.1pt;">/s/ </span>Brian M. Hahn</p></td></tr><tr><td style="vertical-align:top;width:29.85%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><span style="letter-spacing:-0.1pt;white-space:pre-wrap;">Date:  </span>August 5, 2021</p></td><td style="vertical-align:top;width:20.14%;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="letter-spacing:-0.1pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;border-top:1px solid #000000;margin:0pt;padding:0pt 0.69pt 0pt 0.69pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Brian M. Hahn<br />Senior Vice President and Chief Financial Officer </p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>glyc-20210730xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 8/5/2021 12:00:19 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT 99.1</b></p><p style="font-family:'Courier New';font-size:12pt;font-weight:bold;line-height:1.19;text-align:justify;text-transform:uppercase;margin:0pt 41.75pt 0pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;"><img src="glyc-20210730xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:58.4pt;width:271pt;"></b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Courier New';font-size:12pt;font-weight:bold;line-height:1.19;text-align:center;text-transform:uppercase;margin:0pt 41.75pt 0pt 36pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:14pt;text-transform:none;visibility:hidden;margin:24pt 0pt 18pt 0pt;">&#8203;</font></p><p style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:0.9pt;">GLYCOMIMETICS REPORTS HIGHLIGHTS AND FINANCIAL RESULTS </b></p><p style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;letter-spacing:0.9pt;">FOR SECOND QUARTER 2021</b></p><p style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.79;text-align:center;margin:0pt;"><font style="font-weight:bold;letter-spacing:0.9pt;line-height:1.37;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="background-color:#ffffff;font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="background-color:#ffffff;padding:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:italic;font-weight:normal;line-height:1.19;text-align:left;">Completion of enrollment is expected by year-end 2021 for the Company-sponsored Phase 3 pivotal trial evaluating uproleselan in patients with relapsed/refractory acute myeloid leukemia (AML)</i></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="background-color:#ffffff;font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="background-color:#ffffff;padding:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:italic;font-weight:normal;line-height:1.19;text-align:left;">Completion of enrollment is expected by year-end 2021 for the Phase 2 portion of the NCI-sponsored Phase 2/3 registration trial evaluating uproleselan in newly diagnosed AML patients fit for chemotherapy </i></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="background-color:#ffffff;font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="background-color:#ffffff;padding:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:italic;font-weight:normal;line-height:1.19;text-align:left;">During the quarter and shortly after the quarter close, GlycoMimetics announced the initiation of three investigator-sponsored trials (ISTs) to expand the scope of its clinical research with uproleselan in AML and multiple myeloma</i></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="background-color:#ffffff;font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="background-color:#ffffff;padding:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:italic;font-weight:normal;line-height:1.19;text-align:left;">Yesterday, the Company announced that Harout Semerjian will become chief executive officer, effective August 6, to succeed Rachel King, who is retiring </i></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="background-color:#ffffff;font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="background-color:#ffffff;padding:0pt;"><i style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:italic;font-weight:normal;line-height:1.19;text-align:left;">Hosting a conference call and webcast today at&#160;8:30 a.m. ET</i></td></tr></table><div style="margin-top:14pt;"></div><p style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;padding-bottom:12pt;margin:0pt;"><b style="font-weight:bold;">ROCKVILLE, MD, August 5, 2021--</b>&#160;GlycoMimetics, Inc.&#160;(Nasdaq: GLYC) today reported its financial results for the quarter ended&#160;June 30, 2021&#160;and highlighted recent events. Cash and cash equivalents at&#160;June 30, 2021&#160;were&#160;$118.9 million.</p><p style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;padding-bottom:12pt;margin:0pt;">&#8220;There are now six trials underway evaluating our lead clinical candidate, uproleselan, including three registration trials and three ISTs, which we anticipate will provide clinical data flow beginning in 2022. Importantly, recruitment rates in both our Company-sponsored Phase 3 trial and the National Cancer Institute&#8217;s Phase 2 portion of the Phase 2/3 trial support our expectation that enrollment in both studies can be completed by the end of this year. <a name="_Hlk78801090"></a><font style="white-space:pre-wrap;">The support of clinicians who are enrolling patients in our global studies, and now the new ISTs, has made it possible to broaden the scope of  our uproleselan clinical research to address unmet needs in AML and beyond,&#8221; commented&#160; Chief Executive Officer Rachel King.</font></p><p style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;padding-bottom:10pt;margin:0pt;"><b style="font-weight:bold;">Operational Highlights</b></p><p style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Uproleselan</b></p><div style="margin-top:14pt;"></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="background-color:#ffffff;font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">&#9679;</td><td style="background-color:#ffffff;padding:0pt 0pt 12pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Enrollment of GlycoMimetics&#8217; pivotal Phase 3 trial in relapsed/refractory AML continued in the&#160;U.S.,&#160;Canada, Australia&#160;and&#160;Europe&#160;at a steady pace throughout the second quarter of 2021. The Company continues to project that enrollment will be completed by year-end 2021.</font></td></tr></table></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:always;width:79.41%;border-width:0;"><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="background-color:#ffffff;font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt 0pt 12pt 0pt;">&#9679;</td><td style="background-color:#ffffff;padding:0pt 0pt 12pt 0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">The pace of enrollment in the National Cancer Institute (NCI)-sponsored Phase 2/3 registration trial, designed to evaluate the use of uproleselan in newly diagnosed older adults with AML who are fit for chemotherapy, continues to support the Company&#8217;s expectation that the Phase 2 portion will complete in 2021, and allow for a subsequent interim Event-Free Survival analysis of 262 patients.</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="background-color:#ffffff;font-family:'Times New Roman';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="background-color:#ffffff;padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">During the quarter and shortly after the quarter close, clinicians initiated three ISTs designed to evaluate uproleselan in AML and in bone marrow transplantation for multiple myeloma. These trials are expected to begin producing clinical data in 2022, which the Company believes will support the potential of uproleselan to be used as a foundational treatment in AML to overcome well-established mechanisms of leukemic cell resistance within the bone marrow microenvironment and reduce adverse effects of chemotherapy.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">GMI-1359</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">In&#160;April 2021&#160;at the American Association for Cancer Research (AACR) meeting,&#160;Duke University&#160;clinicians </font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;"><a name="_Hlk78021714"></a></font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">reported biologic activity, as demonstrated by cell mobilization, redistribution of immune subset profiles and changes in other pharmacodynamic markers, observed in the initial two patients treated in the ongoing Phase 1b study in patients with advanced breast cancer with bone metastases. The initial clinical data support the dual functionality of the compound and the potential of GMI-1359 to enhance responses to chemo and immune therapies.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">GMI-1687</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.27;text-align:left;">The Company continued to advance GMI-1687 towards filing of an investigational new drug application (IND), anticipated in the first half of 2022.</font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.27;margin:0pt 0pt 0pt 36pt;"><font style="line-height:1.37;margin-bottom:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt;"><b style="font-weight:bold;">Management Transition</b></p><p style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt;"><font style="font-weight:bold;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">Yesterday, the Company announced that its Board of Directors has appointed Harout</font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;"> Semerjian as </font><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">chief executive officer (CEO), effective August 6, 2021, to succeed Founding CEO Rachel King. Mrs. King, who has served as CEO since the Company&#8217;s founding, has decided to retire for personal reasons and will continue her involvement with the Company through her role on the Board of Directors and serving as an advisor during a transition period. Mr. Semerjian, a seasoned executive with strong commercial oncology experience, will lead the Company as it advances its registration trials for uproleselan in AML, accelerates planning for potential commercialization, and continues to build out the Company&#8217;s pipeline.</font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 8pt 36pt;"><font style="line-height:1.37;margin-bottom:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Second Quarter 2021 Financial Results</b></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;white-space:pre-wrap;">Cash position: As of June 30, 2021, GlycoMimetics had cash and cash equivalents of $118.9 million as compared to $137.0 million as of December 31, 2020.  </font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><font style="line-height:1.37;margin-bottom:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;">R&amp;D Expenses: Research and development expenses increased to $10.2 million for the quarter ended June 30, 2021 as compared to $9.9 million for the quarter ended June 30, 2020. This increase was primarily due to an increase in clinical trial costs in our ongoing global Phase 3 clinical trial of uproleselan in individuals with relapsed/refractory AML.</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 18pt;"><font style="line-height:1.37;margin-bottom:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:always;width:79.41%;border-width:0;"><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;white-space:pre-wrap;">G&amp;A Expenses: General and administrative expenses were $4.2 million for the second quarter ended June 30, 2021 and 2020.  </font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="line-height:1.37;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;font-style:normal;font-weight:normal;line-height:1.19;text-align:left;white-space:pre-wrap;">Shares Outstanding:  Shares of common stock outstanding as of June 30, 2021 were 51,539,010.</font></td></tr></table><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 12pt 36pt;"><font style="line-height:1.37;margin-bottom:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;padding-bottom:12pt;margin:0pt;">The Company will host a conference call and webcast today at&#160;8:30 a.m. ET. The dial-in number for the conference call is (844) 413-7154 for domestic participants and (216) 562-0466 for international participants, with participant code 9977599. Participants are encouraged to connect 15 minutes in advance of the call to ensure they are able to connect. A webcast replay will be available via the &#8220;Investors&#8221; tab on the&#160;GlycoMimetics&#160;website for 30 days following the call. A dial-in phone replay will be available for 24 hours after the close of the call by dialing (855) 859-2056 for domestic participants and (404) 537-3406 for international participants, with participant code 9977599.</p><p style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;padding-bottom:10pt;margin:0pt;"><b style="font-weight:bold;">About Uproleselan</b></p><p style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;padding-bottom:10pt;margin:0pt;">Discovered and developed by&#160;GlycoMimetics, uproleselan is an investigational, first-in-class, targeted inhibitor of E-selectin. Uproleselan (yoo&#8217; pro le&#8217; sel an), currently in a comprehensive Phase 3 development program in AML, has received Breakthrough Therapy Designation from the&#160;U.S.&#160;FDA and from the&#160;Chinese National Medical Products Administration&#160;for the treatment of adult AML patients with relapsed or refractory disease. Uproleselan is designed to block E-selectin (an adhesion molecule on cells in the bone marrow) from binding with blood cancer cells as a targeted approach to disrupting well-established mechanisms of leukemic cell resistance within the bone marrow microenvironment. In a Phase 1/2 clinical trial, uproleselan was evaluated in both newly diagnosed elderly and relapsed or refractory patients with AML. In both populations, patients treated with uproleselan together with standard chemotherapy achieved better-than-expected remission rates and overall survival compared to historical controls, which have been derived from results from third-party clinical trials evaluating standard chemotherapy, as well as lower-than-expected induction-related mortality rates. Treatment in these patient populations was generally well-tolerated, with fewer than expected adverse effects.</p><p style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;padding-bottom:12pt;margin:0pt;"><b style="font-weight:bold;">About GMI-1359</b></p><p style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;padding-bottom:12pt;margin:0pt;">GMI-1359 is designed to simultaneously inhibit both E-selectin and CXCR4, which are adhesion molecules involved in tumor trafficking and metastatic spread. Preclinical studies indicate that targeting both E-selectin and CXCR4 with a single compound could improve efficacy in the treatment of cancers that involve the bone marrow, such as AML and multiple myeloma, or in solid tumors that metastasize to the bone, such as prostate cancer and breast cancer, as well as in osteosarcoma, a rare pediatric tumor affecting about 900 adolescents a year in&#160;the United States. GMI-1359 completed a Phase 1 clinical trial in healthy volunteers, and a Phase 1b clinical study designed to enable investigators to study dose ranging and to generate initial biomarker data around the drug&#8217;s activity in breast cancer patients is in progress. In the first two patients evaluated, the study showed evidence of on-target effects, immune-activation and cell mobilization. GMI-1359 has received Orphan Drug Designation and Rare Pediatric Disease Designation from the FDA for the treatment of osteosarcoma.</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:always;width:79.41%;border-width:0;"><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;padding-bottom:12pt;margin:0pt;"><b style="font-weight:bold;">About GMI-1687</b></p><p style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;padding-bottom:12pt;margin:0pt;">Discovered and developed by&#160;GlycoMimetics, GMI-1687 is a highly-targeted, highly-potent E-selectin antagonist. It has been shown in preclinical studies to be bioavailable via subcutaneous administration. During 2020, data from oral presentations at major scientific conferences pointed to the potential for a self-administered drug to treat VOC of sickle cell disease. Previously,&#160;GlycoMimetics&#160;demonstrated in preclinical models that GMI-1687 could be a potentially self-administered drug to be used in treatment of AML. The investigational drug also represents a potential life-cycle extension opportunity for uproleselan.</p><p style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;padding-bottom:12pt;margin:0pt;"><b style="font-weight:bold;">About&#160;GlycoMimetics, Inc.</b></p><p style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;padding-bottom:12pt;margin:0pt;">GlycoMimetics&#160;is a clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including acute myeloid leukemia (AML), and for inflammatory diseases with high unmet need. The Company&#8217;s science is based on an understanding of the role that carbohydrates play on the surface of every living cell and applying its specialized chemistry platform to discover small molecule drugs, known as glycomimetics, which alter these carbohydrate-mediated pathways in a variety of disease states, including signaling in cancer and inflammation. As a leader in this space, GlycoMimetics is leveraging this unique targeted approach to advance its pipeline of wholly owned drug candidates, with the goal of developing transformative therapies for serious diseases.&#160;GlycoMimetics&#160;is located in&#160;Rockville, MD&#160;in the&#160;BioHealth Capital Region. Learn more at&#160;www.glycomimetics.com.</p><p style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;padding-bottom:12pt;margin:0pt;"><b style="font-weight:bold;">Forward-Looking Statements</b></p><p style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;padding-bottom:12pt;margin:0pt;">This press release contains forward-looking statements. These forward-looking statements include those relating to the planned or potential clinical development of the Company&#8217;s product candidates, as well as the presentation of data from preclinical studies and clinical trials, and the potential benefits and impact of the Company&#8217;s drug candidates. Actual results may differ materially from those described in these forward-looking statements. For a further description of the risks associated with these statements, as well as other risks facing&#160;GlycoMimetics, please see the risk factors described in the Company&#8217;s annual report on Form 10-K filed with the&#160;U.S. Securities and Exchange Commission&#160;(SEC) on&#160;March 2, 2021, and other filings&#160;GlycoMimetics&#160;makes with the&#160;SEC&#160;from time to time. Forward-looking statements speak only as of the date of this release, and&#160;GlycoMimetics&#160;undertakes no obligation to update or revise these statements, except as may be required by law.</p><p style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.79;padding-bottom:21pt;text-align:center;margin:0pt;">###</p><p style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.79;margin:0pt 0pt 21pt 0pt;">Investor Contact:<br>Shari Annes<br>Phone: 650-888-0902<br>Email:&#160;sannes@annesassociates.com</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:always;width:79.41%;border-width:0;"><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.79;margin:0pt 0pt 10pt 0pt;">Media Contact:<br>Jamie Lacey-Moreira<br>Phone: 410-299-3310<br>Email:&#160;jamielacey@presscommpr.com<font style="white-space:pre-wrap;">   </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="line-height:1.37;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:always;width:79.41%;border-width:0;"><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:12pt;">GlycoMimetics, Inc.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:12pt;">Condensed Statements of Operations</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:12pt;">(In thousands, except share and per share data)</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:12pt;line-height:1.37;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Courier New';font-size:12pt;font-weight:bold;line-height:1.19;text-align:center;text-transform:uppercase;margin:0pt 41.75pt 0pt 41.75pt;"><font style="visibility:hidden;margin:24pt 0pt 18pt 0pt;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:45.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three months ended June 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six Months ended June 30,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="13" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.95%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Unaudited)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Unaudited)</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">Revenue</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> &#8212;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 1,056</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 9,000</font></p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">Costs and expenses:</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 18pt;">Research and development expense</p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 18pt;"><font style="font-size:10pt;margin-bottom:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 10,167</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 9,871</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 21,315</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 22,539</font></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 18pt;">General and administrative expense</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 18pt;"><font style="font-size:10pt;margin-bottom:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 4,237</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 4,235</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 8,425</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 8,675</font></p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 30pt;">Total costs and expenses</p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 30pt;"><font style="font-size:10pt;margin-bottom:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 14,404</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 14,106</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 29,740</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 31,214</font></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">Loss from operations</p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (14,404)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (14,106)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (28,684)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (22,214)</font></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">Interest income </p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 5</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 27</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 11</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 472</font></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">Net loss and comprehensive loss</p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (14,399)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (14,079)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (28,673)</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (21,742)</font></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">Net loss per common share &#8211; basic and diluted</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (0.28)</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (0.32)</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (0.56)</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> (0.50)</font></p></td></tr><tr><td style="vertical-align:bottom;width:45.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">Weighted-average common shares &#8211; basic and diluted</p></td><td style="vertical-align:bottom;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 51,539,010</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 43,801,251</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 51,118,096</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 43,688,420</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="line-height:1.37;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:always;width:79.41%;border-width:0;"><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:12pt;">GlycoMimetics, Inc.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:12pt;">Balance Sheet Data</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:12pt;">(In thousands)</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:68.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">June 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;font-weight:bold;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2020</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.45%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(unaudited)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.13%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b><font style="font-weight:bold;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:68.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 118,854</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 137,035</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">Working capital</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 110,066</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 125,845</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">Total assets</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 124,379</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 142,832</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">Total liabilities</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 12,092</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 14,613</font></p></td></tr><tr><td style="vertical-align:bottom;width:68.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="background-color:#cceeff;vertical-align:bottom;width:68.4%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;">Total stockholders&#39; equity</p></td><td style="background-color:#cceeff;vertical-align:bottom;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.69%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 112,286</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 0.05pt 0pt;"><font style="font-size:10pt;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></td><td style="background-color:#cceeff;vertical-align:bottom;white-space:nowrap;width:11.73%;margin:0pt;padding:0pt;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;line-height:1.37;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><font style="white-space:pre-wrap;"> 128,219</font></p></td></tr></table></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>glyc-20210730xex99d2.htm
<DESCRIPTION>EX-99.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.11.0.85--><!--Created on: 8/5/2021 12:00:22 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;text-align:right;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">EXHIBIT 99.2</b></p><p style="font-family:'Courier New';font-size:12pt;font-weight:bold;line-height:1.19;text-align:justify;text-transform:uppercase;margin:0pt 41.75pt 0pt 0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;"><img src="glyc-20210730xex99d2001.jpg" alt="Graphic" style="display:inline-block;height:58.4pt;width:271pt;"></b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.37;margin:0pt 0pt 10pt 0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Courier New';font-size:12pt;font-weight:bold;line-height:1.19;text-align:center;text-transform:uppercase;margin:0pt 41.75pt 0pt 36pt;"><font style="font-family:'Calibri','Helvetica','sans-serif';font-size:14pt;text-transform:none;visibility:hidden;margin:24pt 0pt 18pt 0pt;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt 0pt 10pt 0pt;"><b style="font-size:12pt;font-weight:bold;">GLYCOMIMETICS NAMES HAROUT SEMERJIAN AS NEW CHIEF EXECUTIVE OFFICER TO SUCCEED RETIRING CEO RACHEL KING</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><i style="font-size:12pt;font-style:italic;">Mrs. King, the company&#8217;s founding CEO, will remain a Director and advisor to support transition </i></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:12pt;line-height:1.37;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-size:12pt;line-height:1.37;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.79;margin:0pt;"><b style="font-weight:bold;">Rockville, MD, August 4, 2021</b><font style="white-space:pre-wrap;"> &#8212; GlycoMimetics, Inc.  (Nasdaq: GLYC) today announced that its Board of Directors has appointed </font>Harout Semerjian as chief executive officer (CEO), effective August 6, 2021, to succeed retiring Founding CEO Rachel King. Mr. Semerjian, a seasoned executive with strong oncology commercialization experience, will lead the company as it advances its registrational trials on its lead clinical candidate, uproleselan, in acute myeloid leukemia (AML), accelerates planning for potential commercialization, and continues to build out the company&#8217;s pipeline.</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.79;margin:0pt;"><font style="line-height:1.37;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.79;margin:0pt;"><font style="white-space:pre-wrap;">Tim Pearson, Chairman of the Board of Directors of GlycoMimetics, said, &#8220;On behalf of the entire Board, I offer sincere thanks to Rachel for her leadership of GlycoMimetics and for her commitment to the company&#8217;s employees and to patients who will hopefully benefit from GlycoMimetics&#8217; technology.  We look forward to her continued contributions as a board member.&#8221;  </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.79;margin:0pt;"><font style="line-height:1.37;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.79;margin:0pt;"><font style="white-space:pre-wrap;">Mr. Pearson continued, &#8220;Harout is ideally positioned to lead GlycoMimetics into the company&#8217;s next phase of growth as we anticipate the completion of our Phase 3 trial and potential commercialization of uproleselan.  He possesses the right leadership and operational skills as well as tremendous know-how from his many years at Novartis overseeing several oncology and hematology product launches and from subsequent C-level positions he has held within the industry.  I am confident Harout will be an effective leader for GlycoMimetics into the future.&#8221;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.79;margin:0pt;"><font style="line-height:1.37;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:always;width:79.41%;border-width:0;"><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.79;margin:0pt;">Mrs. King, who has served as CEO for 18 years, has decided to retire for personal reasons and will continue her involvement with the company through her role on the Board of Directors and serving as an advisor during this transition. Mrs. King led GlycoMimetics&#8217; evolution from an early venture-backed company through its initial public offering, strategic partnerships and the advancement of two late-stage clinical candidates. She also shepherded the company&#8217;s unique and productive glycochemistry platform to build a multi-faceted pipeline of drug candidates targeting key unmet needs in oncology, sickle cell disease and other indications. </p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.79;margin:0pt;"><font style="line-height:1.37;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.79;margin:0pt;">&#8220;It has been a privilege and a pleasure to lead GlycoMimetics and to work with such an extraordinary team of colleagues,&quot; said&#160;Mrs. King. &#8220;I am extremely proud of what we have collectively accomplished in the 18 years since the company was founded. When I approached the Board to let them know that I was considering retirement, I committed to do all I can to ensure a smooth transition. I look forward to working with Harout and the team as a board member to continue to advance our programs. My decision to focus on spending more time with my family seems appropriately timed as&#160;we&#160;near an opportunity to commercialize our first product candidate.&#8221;&#160;</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.79;margin:0pt;"><font style="line-height:1.37;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.79;margin:0pt;"><font style="white-space:pre-wrap;">Mr. Semerjian is a global biopharmaceutical veteran. Over the last 25 years, he acquired extensive US, European and international commercialization experience having led multiple successful hematology/oncology product launches, including preparation for the launch of midostaurin in AML. During his 16-year tenure at Novartis, Mr. Semerjian held both strategic and operational leadership roles including US Hematology franchise head. He then served as EVP, chief commercial officer at Ipsen where he was accountable for worldwide commercialization and portfolio strategy. Most recently, he briefly served as CEO of Immunomedics before its sale to Gilead Sciences, Inc.  </font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.79;margin:0pt;"><font style="line-height:1.37;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.79;margin:0pt;">&#8220;I believe GlycoMimetics has exciting opportunities ahead. Uproleselan is a differentiated drug candidate already recognized by both FDA and the Chinese regulatory authority with Breakthrough Therapy Designations and the potential for significant impact across the spectrum of AML. The enthusiasm of independent investigators as well as the clinicians participating in our registration trials provides a foundation for a successful commercialization plan, should the readout and regulatory interactions prove positive. While there are just a few glycobiology-based therapeutics on the market today, the field of glycobiology is rapidly advancing and ripe with opportunity. The expertise resident in GlycoMimetics underlies my confidence in its platform&#8217;s productivity. Across the pipeline, I&#8217;m seeing novel and potentially game-changing therapies,&#8221; </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:always;width:79.41%;border-width:0;"><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.79;margin:0pt;"><font style="white-space:pre-wrap;"> said Mr. Semerjian. &#8220;I look forward to working with the outstanding team at GlycoMimetics as we strive to make a difference in the lives of patients with cancer and other diseases.&#8221;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="line-height:1.37;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p><p style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;padding-bottom:21pt;margin:0pt;"><b style="font-weight:bold;">About&#160;GlycoMimetics, Inc.</b></p><p style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.79;margin:0pt;">GlycoMimetics&#160;is a clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including acute myeloid leukemia (AML), and for inflammatory diseases with high unmet need. The Company&#8217;s science is based on an understanding of the role that carbohydrates play on the surface of every living cell and applying its specialized chemistry platform to discover small molecule drugs, known as glycomimetics, that alter these carbohydrate-mediated pathways in a variety of disease states, including signaling in cancer and inflammation. As a leader in this space, GlycoMimetics is leveraging this unique targeted approach to advance its pipeline of wholly owned drug candidates, with the goal of developing transformative therapies for serious diseases. The Company&#8217;s lead drug candidate, uproleselan, has received Breakthrough Therapy Designation in the&#160;U.S.&#160;and&#160;China&#160;and is undergoing evaluation across a range of patient populations, including a Phase 3 trial in relapsed/refractory AML.&#160;GlycoMimetics&#160;is located in&#160;Rockville, MD&#160;in the&#160;BioHealth Capital Region. Learn more at&#160;www.glycomimetics.com.</p><p style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.79;margin:0pt;"><font style="line-height:1.37;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p><p style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.79;padding-bottom:21pt;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Forward-Looking Statements  </b></p><p style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.79;padding-bottom:21pt;margin:0pt;">This press release contains forward-looking statements. These forward-looking statements include those relating to the planned or potential clinical development, and the potential benefits and impact, of the Company&#8217;s product candidate, uproleselan, as well as the potential commercialization of uproleselan if it is approved. Actual results may differ materially from those described in these forward-looking statements. For a further description of the risks associated with these statements, as well as other risks facing&#160;GlycoMimetics, please see the risk factors described in the Company&#8217;s annual report on Form 10-K filed with the&#160;U.S. Securities and Exchange Commission&#160;(SEC) on&#160;March 2, 2021, and other filings&#160;GlycoMimetics&#160;makes with the&#160;SEC&#160;from time to time. Forward-looking statements speak only as of the date of this release, and&#160;GlycoMimetics&#160;undertakes no obligation to update or revise these statements, except as may be required by law.</p><p style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.79;padding-bottom:21pt;text-align:center;margin:0pt;">###</p><p style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.79;padding-bottom:21pt;text-align:center;margin:0pt;"><font style="line-height:1.37;margin-bottom:10pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:always;width:79.41%;border-width:0;"><div style="max-width:100%;padding-left:10.29%;padding-right:10.29%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="background-color:#ffffff;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt 0pt 21pt 0pt;">Investor Contact:<br>Shari Annes<br>Phone: 650-888-0902<br>Email:&#160;sannes@annesassociates.com</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;">Media Contact:<br>Jamie Lacey-Moreira<br>Phone: 410-299-3310<br>Email:&#160;jamielacey@presscommpr.com<font style="white-space:pre-wrap;">   </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:10.29%;margin-right:10.29%;margin-top:30pt;page-break-after:avoid;width:79.41%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>glyc-20210730xex99d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 glyc-20210730xex99d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !. 6D# 2(  A$! Q$!_\0
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M\_Q#X#OK:S'+W%K.)M@]2 ,#\2*[?P_XBTOQ/IBZAI-TL\!.&[,C?W6!Y!H
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M'COX:]?\RS1117I'E!1110 5RWC#_5?"K_KK_P"SP5U-<MXP_P!5\*O^NO\
M[/!7#C=HGHX#[7R_4]%^*NMW&A?#W4;BT8I<3;;='!P4WG!(]]N<>^*T_!?A
M:T\(^&[;3K>)%FV!KF0=99<?,2?KT]!4'Q#\.2^*?!&H:;;X^U%1+ #W=#D#
M\<$?C5/X?>-[7Q-I,5G=2>1KMHOE7=I+\LFY>"P!Y(/?T/!K@/0.PDG@B.V6
M6-"1T9@,U0TC3-%TOSTTBVM+<SN991;@#<Q[G'U^@K*\6>$/"6MD:IXEM8W%
MM%M\^6Y>)43)/.U@.I-</\)M&T^7QCK_ (BT.R>TT$)]BL@S,?-Y4NV6)/5
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MM\2WCG\27#:)H(P8["%=K%>WR?U;\!7J7ASPGHOA2S^S:18I#D 22GYI)/\
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&1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>glyc-20210730xex99d2001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 glyc-20210730xex99d2001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !. 6D# 2(  A$! Q$!_\0
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M\_Q#X#OK:S'+W%K.)M@]2 ,#\2*[?P_XBTOQ/IBZAI-TL\!.&[,C?W6!Y!H
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M'COX:]?\RS1117I'E!1110 5RWC#_5?"K_KK_P"SP5U-<MXP_P!5\*O^NO\
M[/!7#C=HGHX#[7R_4]%^*NMW&A?#W4;BT8I<3;;='!P4WG!(]]N<>^*T_!?A
M:T\(^&[;3K>)%FV!KF0=99<?,2?KT]!4'Q#\.2^*?!&H:;;X^U%1+ #W=#D#
M\<$?C5/X?>-[7Q-I,5G=2>1KMHOE7=I+\LFY>"P!Y(/?T/!K@/0.PDG@B.V6
M6-"1T9@,U0TC3-%TOSTTBVM+<SN991;@#<Q[G'U^@K*\6>$/"6MD:IXEM8W%
MM%M\^6Y>)43)/.U@.I-</\)M&T^7QCK_ (BT.R>TT$)]BL@S,?-Y4NV6)/5
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MM\2WCG\27#:)H(P8["%=K%>WR?U;\!7J7ASPGHOA2S^S:18I#D 22GYI)/\
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&1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>glyc-20210730.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7811.37134 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/5/2021 12:00:32 PM-->
<!--Modified on: 8/5/2021 12:00:32 PM-->
<xsd:schema targetNamespace="http://www.glycomimetics.com/20210730" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:us-roles="http://fasb.org/us-roles/2020-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:currency="http://xbrl.sec.gov/currency/2020-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2020-01-31" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exch="http://xbrl.sec.gov/exch/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:sic="http://xbrl.sec.gov/sic/2020-01-31" xmlns:us-types="http://fasb.org/us-types/2020-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:attributeFormDefault="unqualified" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:glyc="http://www.glycomimetics.com/20210730">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="glyc-20210730_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="glyc-20210730_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2020-01-31" schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" />
  <xsd:element name="DocumentAndEntityInformationAbstract" id="glyc_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>glyc-20210730_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7811.37134 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/5/2021 12:00:32 PM-->
<!--Modified on: 8/5/2021 12:00:32 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="glyc-20210730.xsd#glyc_DocumentAndEntityInformationAbstract" xlink:label="glyc_DocumentAndEntityInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="glyc_DocumentAndEntityInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="glyc_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Written Communications</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Soliciting Material</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pre-commencement Issuer Tender Offer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>glyc-20210730_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  9.6.7811.37134 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/5/2021 12:00:32 PM-->
<!--Modified on: 8/5/2021 12:00:32 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="glyc-20210730.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="glyc-20210730.xsd#glyc_DocumentAndEntityInformationAbstract" xlink:label="glyc_DocumentAndEntityInformationAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType_637637616328943421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType_637637616328943421" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_637637616328943421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate_637637616328943421" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_637637616328943421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFileNumber_637637616328943421" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_637637616328943421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName_637637616328943421" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_637637616328943421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_637637616328943421" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_637637616328943421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityTaxIdentificationNumber_637637616328943421" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_637637616328943421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressAddressLine1_637637616328943421" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_637637616328943421" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressCityOrTown_637637616328943421" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_637637616328953792" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressStateOrProvince_637637616328953792" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_637637616328953792" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityAddressPostalZipCode_637637616328953792" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_637637616328953792" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_CityAreaCode_637637616328953792" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_637637616328953792" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_LocalPhoneNumber_637637616328953792" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications_637637616328953792" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_WrittenCommunications_637637616328953792" order="13" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial_637637616328953792" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_SolicitingMaterial_637637616328953792" order="14" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer_637637616328953792" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_PreCommencementTenderOffer_637637616328953792" order="15" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer_637637616328953792" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer_637637616328953792" order="16" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_637637616328953792" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_Security12bTitle_637637616328953792" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_637637616328953792" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_TradingSymbol_637637616328953792" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_637637616328963781" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_SecurityExchangeName_637637616328963781" order="19" use="optional" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_637637616328963781" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityEmergingGrowthCompany_637637616328963781" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_637637616328963781" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey_637637616328963781" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_637637616328963781" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="glyc_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag_637637616328963781" order="22" use="optional" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>glyc-20210730x8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="glyc-20210730.xsd" xlink:type="simple"/>
    <context id="Duration_7_30_2021_To_7_30_2021_pgCzPkHsLUKLmV_c3rdOlA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001253689</identifier>
        </entity>
        <period>
            <startDate>2021-07-30</startDate>
            <endDate>2021-07-30</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="Duration_7_30_2021_To_7_30_2021_pgCzPkHsLUKLmV_c3rdOlA"
      id="Tc_7pF5awmX50aep2Cm-n7kKw_2_1">0001253689</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="Duration_7_30_2021_To_7_30_2021_pgCzPkHsLUKLmV_c3rdOlA"
      id="Tc_5XSJHcwKxEmyICLU4DGEVQ_3_1">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="Duration_7_30_2021_To_7_30_2021_pgCzPkHsLUKLmV_c3rdOlA"
      id="Narr_rB8GysNTm0CSPr1mrf-ppw">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_7_30_2021_To_7_30_2021_pgCzPkHsLUKLmV_c3rdOlA"
      id="Narr_14BQy5fNDESIeHefXvN9Yg">2021-07-30</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="Duration_7_30_2021_To_7_30_2021_pgCzPkHsLUKLmV_c3rdOlA"
      id="Narr_ZDhKYrryGEOTnV4VzyrpOg">GlycoMimetics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_7_30_2021_To_7_30_2021_pgCzPkHsLUKLmV_c3rdOlA"
      id="Tc_2jA8yP7LH0K-TKRlJg7mHg_1_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="Duration_7_30_2021_To_7_30_2021_pgCzPkHsLUKLmV_c3rdOlA"
      id="Tc_GkDDAviZLUSXLrs5waAuKw_1_2">001-36177</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_7_30_2021_To_7_30_2021_pgCzPkHsLUKLmV_c3rdOlA"
      id="Tc_7vp7CK_TPUKnRyH7aQ9HCg_1_4">06-1686563</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_7_30_2021_To_7_30_2021_pgCzPkHsLUKLmV_c3rdOlA"
      id="Narr_7K99Wy0vw0S8TFC3b_ge-A">9708 Medical Center Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_7_30_2021_To_7_30_2021_pgCzPkHsLUKLmV_c3rdOlA"
      id="Narr_nXbpgFF33ESPynckHtTs9w">Rockville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_7_30_2021_To_7_30_2021_pgCzPkHsLUKLmV_c3rdOlA"
      id="Narr_NRYXfi3OjUq42Cg6VYh_Bw">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_7_30_2021_To_7_30_2021_pgCzPkHsLUKLmV_c3rdOlA"
      id="Narr_qrzltJ6f0kSHdZFw4vUVTQ">20850</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_7_30_2021_To_7_30_2021_pgCzPkHsLUKLmV_c3rdOlA"
      id="Narr_IHIzlBC55E6OLvQJKRLC1g">240</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_7_30_2021_To_7_30_2021_pgCzPkHsLUKLmV_c3rdOlA"
      id="Narr_ZfIdqT63I02X_zlC96ISpQ">243-1201</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="Duration_7_30_2021_To_7_30_2021_pgCzPkHsLUKLmV_c3rdOlA"
      id="Narr_4xoBKF3khkOXMkANYIlx9g">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="Duration_7_30_2021_To_7_30_2021_pgCzPkHsLUKLmV_c3rdOlA"
      id="Narr_beRiTy4ESEGWT3EnXu3pgQ">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="Duration_7_30_2021_To_7_30_2021_pgCzPkHsLUKLmV_c3rdOlA"
      id="Narr_H0BFx0MWyUyY2JArNA954g">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="Duration_7_30_2021_To_7_30_2021_pgCzPkHsLUKLmV_c3rdOlA"
      id="Narr_CDZ3HTtu8E-XOgD7eiZGcA">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="Duration_7_30_2021_To_7_30_2021_pgCzPkHsLUKLmV_c3rdOlA"
      id="Tc_F0jw50_sMUCPG2VbMb4U_A_2_0">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_7_30_2021_To_7_30_2021_pgCzPkHsLUKLmV_c3rdOlA"
      id="Tc_Vmada2zcaEO2f3Olx6y-kg_2_1">GLYC</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_7_30_2021_To_7_30_2021_pgCzPkHsLUKLmV_c3rdOlA"
      id="Tc_qOEo9bOdsk-tOzW80vbm5A_2_2">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_7_30_2021_To_7_30_2021_pgCzPkHsLUKLmV_c3rdOlA"
      id="Narr_DHBOx83_s0qVgv8ygl3ixg">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140102293952280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Jul. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_glyc_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jul. 30,  2021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">GlycoMimetics, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">06-1686563<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9708 Medical Center Drive<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Rockville<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">243-1201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GLYC<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001253689<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_glyc_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">glyc_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>glyc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>11
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MCMQC)8QQ8K3^-8+)#^Q^ %!+ P04    "  ;0 53'#AEZC\!   \ @  #P
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M=Y-[2:AU[D&P]_ :C1W-CQ^W_ %02P,$%     @ &T %4R0>FZ*M    ^ $
M !H   !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<[61/0Z#, R%KQ+E #50
MJ4,%3%U8*RX0!?,C$A+%K@JW+X4!D#IT8;*>+7_OR4Z?:!1W;J"V\R1&:P;*
M9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!V#-DGNZ9HIP\_D-T==UI
M?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6HJ@R&8HJEG!:(.+)(&UI
M5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0    ( !M !5-ED'F2&0$
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M;W!S+V%P<"YX;6Q02P$"% ,4    "  ;0 53A=J:\^X    K @  $0
M        @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    "  ;0 53
MF5R<(Q &  "<)P  $P              @ ', 0  >&PO=&AE;64O=&AE;64Q
M+GAM;%!+ 0(4 Q0    ( !M !5-A&@'U- 0  & 0   8              "
M@0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    "  ;0 53
MGZ ;\+$"  #B#   #0              @ %W#   >&PO<W1Y;&5S+GAM;%!+
M 0(4 Q0    ( !M !5.7BKL<P    !,"   +              "  5,/  !?
M<F5L<R\N<F5L<U!+ 0(4 Q0    ( !M !5,<.&7J/P$  #P"   /
M      "  3P0  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  ;0 53)!Z;
MHJT   #X 0  &@              @ &H$0  >&PO7W)E;',O=V]R:V)O;VLN
M>&UL+G)E;'-02P$"% ,4    "  ;0 5399!YDAD!  #/ P  $P
M    @ &-$@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"  #7
%$P     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="glyc-20210730x8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="glyc-20210730x8k.htm">glyc-20210730x8k.htm</File>
    <File>glyc-20210730.xsd</File>
    <File>glyc-20210730_lab.xml</File>
    <File>glyc-20210730_pre.xml</File>
    <File>glyc-20210730xex99d1.htm</File>
    <File>glyc-20210730xex99d2.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "glyc-20210730x8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "glyc-20210730x8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "glyc-20210730_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "glyc-20210730_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "glyc-20210730.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2020-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "glyc",
   "nsuri": "http://www.glycomimetics.com/20210730",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20210730x8k.htm",
      "contextRef": "Duration_7_30_2021_To_7_30_2021_pgCzPkHsLUKLmV_c3rdOlA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "role": "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "glyc-20210730x8k.htm",
      "contextRef": "Duration_7_30_2021_To_7_30_2021_pgCzPkHsLUKLmV_c3rdOlA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.glycomimetics.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "glyc_DocumentAndEntityInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document and Entity Information [Abstract]"
       }
      }
     },
     "localname": "DocumentAndEntityInformationAbstract",
     "nsuri": "http://www.glycomimetics.com/20210730",
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001558370-21-010404-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-21-010404-xbrl.zip
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M-: NX+<!F=G>;/]O=:$/N2SNG)NB47[YVB#;KFL3=O$;4$L#!!0    ( !M
M!5-\:LM+CP4  -<\   5    9VQY8RTR,#(Q,#<S,%]L86(N>&ULU9OO;^(V
M',;?3]K_\!WW9I,NA,!NO:*V)Z[7FZK1*SJ8=MHTG4)BP%JPD6,*_/>SDYB2
MU Z_JF#>M&G\^/'W,1\<!]*K#\MI!$^(Q9B2ZYI7;]0 D8"&F(RO:_/8\>,
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MRNUH&D4UBWOK]!4Q]6*AM1LWO'O!ZN-_4$L#!!0    ( !M !5/%4\&/?R@
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M[SW;M]T.7-L#N6Z EHOS&2%J#ZO)5!MA#W=87R>77X#P/'&O02\ NC]-UIL
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MJ(X:>BBK(M_HD^3N@Q8XFF&:R"M#-L,,9#/,I MFTA93^'* IQ>K)3TW1Y>
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M5)_E]8[1E$H9B,]FODW:S?@P SI@@QKMN$Z74K<L:HF6R5<'9#QTKE4Q[U:
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MC:#&Q*P?_#MS+9=UDZV=<.-&7::%":".B8_2!2!7*PS2QL!,LN8@D_&;2;A
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M5,C]4*#*#&'J"OT&'@8>)8#'>R&5;46)(_P^"QE@@@"%/"73[UG/H<#7D0
M$1K]\I-]8IVUNPV+T-JH1JYN%[#Q_'2!BJ5EZ8+7#8XT3K.,0QJZJ ?1HP-
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M>_?9C<FZ4,(%([B*=<ZQ<KM303U]2S#,#]O-YA%IVHWJJ=UJJC-=,<*,JT/
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M   1              "  0    !G;'EC+3(P,C$P-S,P+GAS9%!+ 0(4 Q0
M   ( !M !5-\:LM+CP4  -<\   5              "  =(#  !G;'EC+3(P
M,C$P-S,P7VQA8BYX;6Q02P$"% ,4    "  ;0 53&LD:^8X$  !+*0  %0
M            @ &4"0  9VQY8RTR,#(Q,#<S,%]P<F4N>&UL4$L! A0#%
M  @ &T %4\53P8]_*   N@P! !0              ( !50X  &=L>6,M,C R
M,3 W,S!X.&LN:'1M4$L! A0#%     @ &T %4Z/GM[Q1(P  *2D" !@
M         ( !!C<  &=L>6,M,C R,3 W,S!X97@Y.60Q+FAT;5!+ 0(4 Q0
M   ( !M !5/(BPN*71   *,[   8              "  8U:  !G;'EC+3(P
G,C$P-S,P>&5X.3ED,BYH=&U02P4&      8 !@"3 0  (&L

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
